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Summary: A method for the identification and quantification of the antiepileptics lamotrigine, Carbamazepine and
Carbamazepine epoxide (active metabolite) in human serum is described. In refractory epilepsy the combination of
Carbamazepine and lamotrigine was recently developed to a modern therapeutic concept. The goal of this paper is
therapeutic drug monitoring (TDM) of these substances. Serum was extracted with a quick precipitation method
using a modified commercial extraction-kit and analysed by gas chromatography mass Spectrometry (GC-MS). A
gas-chromatographic temperature-pressure programme was developed that allowed the determination of lamotrigine
by gas chromatography mass Spectrometry. A reference spectrum of pure lamotrigine is herewith published for the
first time. A new mass spectra library was created to support the identification of the antiepileptics in human serum.
In the Specified Ions Monitoring mode (SIM) a detection limit below the therapeutic range and recoveries above
90% were obtained.
Comparison of results obtained by GC-MS or a commercially available high performance liquid Chromatographie
(HPLC) method (for lamotrigine) and a fluorescence polarisation immunoassay (FPIA) (for Carbamazepine) from
spiked serum samples showed disagreement of no more than 10% between the methods and demonstrated the
accuracy of the new method. In addition, quantitative determinations of these antiepileptics in samples from patients
under anticonvulsive therapy showed a strong linear correlation with r2 = 0.961 for Carbamazepine and r2 = 0.964
for lamotrigine. Only two from a total of 46 results differed by more than 10%.
Our method for quantifying lamotrigine in serum seems to be highly specific and capable of measuring lamotrigine
in patients on single therapy, as well as on add-on therapy with Carbamazepine or Carbamazepine epoxide. No
interference from other coadministered drugs was detected.
Introduction In this paper we describe the development of a new GC-
Lamotrigine is a new antiepileptic drug and has recently MS method' combined with a modified commercially
shown promise in add-on therapy with other antiepilep- available HPLC extraction ̂  which Save us the Possi-
tic drugs in refractory epilepsy and for resistant partial bil^ to determine lamotrigine together with carbarn-
/1X azepine and Carbamazepine epoxide in blood duringseizures (1). r ±- r o
add-on therapy in one analytical run.
Therapeutic drug monitoring of antiepileptics can help to
optimize therapeutic efficiency and patient safety. The rela-
tionship between the concentration of lamotrigine and Materials and Methods
other antiepileptic drugs in plasma and their therapeutic ef- Reagents
feet has been described in many studies (1—3). Serum con- Carbamazepine was obtained from Abbott Diagnostics (Wiesbaden,
centrations in responding patients receiving chronic treat- Sf"131?', ^Tam™ ̂ ™ standard) frT ̂  ̂_ ° r , ° (Deisenhofen, Germany), lamotngine was purchased from Well-
ment with lamotrigine and exhibiting therapeutic effects come (Wedel, Germany) and drug-free serum from Bio-Rad
were seen to be 0.9— 1.8 mg/1 (4), in practice a therapeutic Laboratories (Munich, Germany). Carbamazepine epoxide was a gift
range from 0.5-4.5 mg/1 was found (5). As with other anti- Jj°? Rf ipff (Mych' Gmoa^ and extraction vials contaming a0 & ^ ' buffered salt mixture were purchased from Recipe (No. 15020).
epileptics, therapy with lamotrigine should be controlled, , . , . . T , , TT_T _ Methanol, acetonitnle and ethylacetate were purchased from Pro-by therapeutic drug monitoring. In the early nineties HPLC mochem GmbH (Wesel, Germany).
and immunoassay determinations of lamotrigine in serum A11 . , , , ,. ,1An„ „ , , . 4. lx ,3 6 All standard solutions (1000 mg/1 solved in methanol) were stored
were described (6-8). However, only HPLC assays have at -70 °C until use, for shorter times (some weeks) storage at
been commercially available up to now. -20 °c seems sufficient.
_ Instrumentation
') Preliminary results were presented as poster at the IFCC con- A Hewlett Packard 5972 Mass Spectrometer combined with a
gress in London 1996 (Proc XVI ICCC 1996, 114). Hewlett Packard 5890 series II plus gas Chromatograph was used.
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It was equipped with a split-splitless injector and a capillary col-
umn DB-5ht (length 30 m, I. D. 0.250 mm, film 0.100 μηι) from
J&W Scientific (ICT, Bad Homburg, Germany).
The gas Chromatographie conditions were: injection temperature
250 °C; transferline heater temperature 325 °C; helium flow-rate
0.815ml/min; injection volume: 2 μΐ splitless. The temperature
programme started at 60 °C, this was held for 2 minutes, within 1
min the temperature was increased to 120 °C and held another 2
min, then the temperature was increased by 20 °C per min and held
finally for l min at 25 °C.
The MS conditions in SCAN-mode were: Tuning masses 264, 219,
131 m/e added with 200 EMV (Electron Multiplier Voltage); mass
range 40-550 m/e, solvent delay 10 min; threshold = 200.
In the SIM-mode the same conditions were used, except that 400
EMV were added. The selected masses for identification and quan-
tification and the ion-group-start time were as shown in table 1.
Carbamazepine was also measured by FPIA using the TDx /FLx
analyzer from Abbott (Wiesbaden, Germany). Lamotrigine was ad-
ditionally measured by reversed phase HPLC. Thereby the same
extraction procedure and a commercially available isocratic HPLC
method with UV-detection from Recipe (Kit No. 15100) were used.
Samples, tubes, storage
Blood was taken in 4.5 ml Vacutainer® serum separator tubes (Bee-
ton Dickinson, Heidelberg, Germany). Serum was stored at 4 °C,
for periods up to 7 days at — 70 °C.
Procedures
Extraction of antiepileptics
In principle a combination of precipitation and liquid extraction
was used. Serum (0.1 ml) and 0.15 ml precipitation reagent (aceto-
nitril containing imipramine 5 mg/1 as internal standard) were
added to the prepared extraction vials. After vortexing for 30 s and
centrifugation (5 min at 10000 g) 0.1 ml of the organic supernatant
was evaporated to dryness with Na at room temperature and the
residue dissolved in 50 μΐ ethylacetate.
Identification of antiepileptic drugs
As peak integrator the Chem-Station-Integrator from Hewlett Pack-
ard was used. Critical conditions were adjusted to: initial area reject
activated, initial peak width 0.020, shoulder detection off, initial
threshold 8.
The conditions for library-search-strategy were: prefilter-control
(U-A) adjusted to 3, tilting to off, crosscorrelation to off, minimum
estimated purity 50%. A library of mass-spectra, prepared by us,
was used for the identification of antiepileptics. It contained
adapted spectra from PMW TOX2 Mass Spectral Database (9) or
NIST/EPA/NIH Mass Spectral Database (Hewlett Packard Com-
pany, Palo Alto, CA) as well as spectra of pure substances exam-
ined by us in the SCAN and SIM modes. The mass spectrum of
lamotrigine was recorded for the first time in our laboratory and
verified with a sector field mass spectrometer at the pharmaceutical
faculty of Ludwig Maximilians University (Munich, Germany).
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Fig. 1 Chromatogram of pure Carbamazepine (3 mg/1) and lamo- trigine was taken from the library database created with our own
trigine (50 mg/1) in the SCAN-mode. The mass spectrum of lamo- standards.
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Fig. 2 Chromatogram in SIM-mode of a patient sample, contain-
ing carbamazepine, carbamazepine epoxide, lamotrigine and imi-
pramine (internal standard, IS). The antiepileptic drugs were ex-
tracted as described in the methods section. The selected masses
and retention times are documented in table 1.
For probabilities greater than 65% we searched the Pfleger-Maurer
(9) library. If this was not successful, we changed automatically to
the library we created. This enabled us in the scan-mode to recog-
nize other drugs in addition. No gas-chromatographic interferences
with the antiepileptics were detected. In the SIM-mode we only
used our own library.
Quantification of antiepileptic drugs
We used the dominant mass of each antiepileptic drug and the
selected internal standard for quantification (tab. 2). The calibration
for carbamazepine epoxide, carbamazepine and lamotrigine was
obtained from six drug free serum samples containing 0; 0.625;
1.25; 2.5; 5.0; 10.0; 20.0 mg/1 of these drugs. Imipramine was used
as internal standard.
Results and Discussion
Identification and quantification of
antiepileptic drugs
Lamotrigine and carbamazepine were extracted from
spiked serum (concentration of lamotrigine was 50 mg/1,
of carbamazepine 6 mg/1) and separated by GC-MS. In
the total ion chromatogram individual peaks were ob-
tained (fig. 1). The extraction procedure of the manufac-
turer for HPLC analysis was changed by drying and re-
dissolving the eluate in pure ethylacetate. This resulted
in a clean extract and gave high recoveries of the antiep-
ileptic drugs. The insert in figure 1 shows the mass
spectrum of lamotrigine. The dominant fragment
mass(es) of each substance were selected for quantifica-
tion (SIM-mode). Due to the low Chromatographie re-
sponse of lamotrogine the signals of three masses
(tab. 2) were used after summation. Figure 2 shows a
chromatogram of lamotrigine, carbamazepine epoxide
and carbamazepine in the SIM-mode together with the
internal standard imipramine. With this procedure the
detection limits (tab. 2) were found to be beyond the
therapeutic levels (4, 5).
Typical calibration curves are given in figure 3. For
all compounds an excellent correlation was found be-
tween standard amount and signal (tab. 3). In addition,
this table shows the intraassay precision data of our
quantification method. CV's were found between 3
and 12%. Accuracy could not be tested with quality
control materials (lacking target values for GC-MS),
but was determined with spiked serum samples. Analy-
sis of 10 to 30 (for lamotrigine) spiked serum samples
showed analytical recoveries between 90 and 111%
for all drugs.
Assay correlation
The results obtained with GC-MS and immunoassay (for
carbamazepine) or HPLC (for lamotrigine) were com-
pared using the Passing-Bablok method. The correlation
coefficients (r2) were higher than 0.95 and the regression
lines obtained for carbamazepine and lamotrigine are
shown in figure 4 a and b. Only two results for lamotrig-
ine disagreed by more than 10%. The results obtained
by GC-MS were repeatedly higher. The nature of the
differences could not be explained, particularly, no such
differences were seen with stock samples.
Concentration [mg/1]
Fig. 3 Calibration curves of carbamazepine (squares), carbama-
zepine epoxide (circles) and lamotrigine (triangles). The concentra-
tions of the standards (extracted from 0.1 ml serum) were 0; 0.625;
1.25; 2.5; 5.0; 10.0; 20.0 mg/1. Imipramine was used as internal
standard (IS). The masses selected for quantification are given in
table 2; linearity is documented in table 3.
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Tab. 3 Non-parametric regression correlation parameters (linearity), recovery and precision data for

















































Therapeutic drug monitoring of antiepileptic drugs is
mainly achieved by immunoassays because these meth-
ods can be mechanized and are computerized. For lamot-
rigine, however, determination by immunoassay, al-
though described in the literature (7, 8), is presently not
commercially available. In recent years several HPLC
methods for quantitation of lamotrigine have been pub-
lished (6). The present GC-MS method, however, has
not been described before. The GC-MS method pre-
sented in this paper seems to be advantageous for mea-
surements of samples from patients on an add-on ther-
apy of lamotrigine with other antiepileptic drugs.
The application of GC-MS is supported by the availabil-
ity of a simple, effective and reproducible sample prepa-
ration procedure. As experienced with various extraction
procedures (10), the use of a modified commercial ex-
traction kit (see procedures) gave a clean extract with
good recovery and precision. Although this step is not
necessary for immunoassay, it opens the possibility to
determine coadministered antiepileptic and other drugs
from the same extract. Together with the advantages
provided by GC-MS, which are achieved by correlation
of two properties (retention time and mass spectrum), a
high certainty of identification is given. This is espe-
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Fig. 4 Comparison of GC-MS and HPLC (immunoassay) results from patient samples.
4a: Lamotrigine (n=23); y = 0.905x - 0.091; r2 = 0.964
4b: Carbamazepine (n=23); y = 0.915x + 0.519; r2 = 0.961
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SIM-mode. The self established spectra of 5 masses al-
low identification of substances with high accuracy. No
interference from other drugs present in patient samples
was observed. The certainty of identification seems at
least to be comparable to HPLC with diode-array-detec-
tion. In future the combination of the excellent chroma-
tographical behaviour of antiepileptics with HPLC and
the selective identification by MS, i. e. LC-MS may be
the most suitable technique possible, probable for TDM
in general.
Under practical aspects GC-MS seems today to be supe-
rior to HPLC because the detection limit (not only signal
to noise ratio) is lower and no change of the column or
solvent is necessary, if another group of compounds has
to be analysed. Therefore the GC-MS equipment can be
used in one sequence (without technical changes) for
confirmation of screening results in drug abuse testing,
for general unknown screening, and e. g. for therapeutic
drug monitoring. This variability cannot be achieved
with HPLC. Laboratories with low sample input should
consider this if they want to establish a Chromato-
graphie technique.
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